Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density in Hepatitis C
NCT00948220Phase 4Completed
- Sponsor
- Ulm University
- Start
- Jul 2003
- Primary completion
- Jan 2007
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 4 trial of peginterferon alfa-2a in hepatitis C virus infection, sponsored by Ulm University. Started Jul 2003; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT00948220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00948220.